WASHINGTON - Two highly publicized deaths of clinical trial participants have prompted lawmakers to look deeper into the rules that govern such research.(BioWorld Today)
Genentech Inc. will strengthen its long-standing relationship with Seattle Genetics Inc. by paying up to $50 million for access to technology to build its cancer program.
Genentech Inc. will strengthen its long-standing relationship with Seattle Genetics Inc. by paying up to $50 million for access to technology to build its cancer program.
MedImmune Inc. agreed to spend an undisclosed amount of money expanding its cancer program through the licensure of two early stage technologies. (BioWorld Today)
MedImmune Inc. agreed to spend an undisclosed amount of money expanding its cancer program through the licensure of two early stage technologies. (BioWorld Today)
A fusion inhibitor for HIV patients being developed by Trimeris Inc. and Hoffmann-La Roche Inc. produced better than expected results in a Phase III trial. (BioWorld Today)
A fusion inhibitor for HIV patients being developed by Trimeris Inc. and Hoffmann-La Roche Inc. produced better than expected results in a Phase III trial. (BioWorld Today)
